Abivax (ABVX) Cash & Equivalents (2021 - 2026)
Abivax (ABVX) posted quarterly Cash & Equivalents of $558.9 million for Q1 2026, up 413.03% year-over-year from $108.9 million in Q1 2025, and down 7.07% quarter-over-quarter from $601.4 million in Q4 2025.
Abivax (ABVX) Cash & Equivalents (2021 - 2026) Analysis & Trends
Abivax's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $558.9 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 413.03% year-over-year to $558.9 million; the TTM figure through Mar 2026 stood at $558.9 million (up 413.03% YoY), while the FY2025 annual figure was $601.4 million, up 290.32% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $558.9 million, down from $601.4 million in the prior quarter.
- The five-year high for Cash & Equivalents was $689.4 million in Q3 2025, with the low at $27.5 million in Q4 2022.
- The 5-year median for Cash & Equivalents is $239.4 million (2024), against an average of $289.1 million.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 885.88% in 2023, then tumbled 71.18% in 2025.
- Abivax's Cash & Equivalents stood at $27.5 million in 2022, then soared by 885.88% to $271.1 million in 2023, then slumped by 43.16% to $154.1 million in 2024, then surged by 290.32% to $601.4 million in 2025, then slipped by 7.07% to $558.9 million in 2026.
- Business Quant data shows ABVX's Cash & Equivalents at $558.9 million in Q1 2026, $601.4 million in Q4 2025, and $689.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 558.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 558.94 Mn |
| Dec 31, 2025 | 601.44 Mn |
| Sep 30, 2025 | 689.40 Mn |
| Jun 30, 2025 | 68.99 Mn |
| Mar 31, 2025 | 108.95 Mn |
| Dec 31, 2024 | 154.09 Mn |
| Sep 30, 2024 | 198.17 Mn |
| Jun 30, 2024 | 239.41 Mn |
| Mar 31, 2024 | 262.47 Mn |
| Dec 31, 2023 | 271.07 Mn |
| Dec 31, 2022 | 27.50 Mn |
| Dec 31, 2021 | 69.44 Mn |